Window of Opportunity Study in Colorectal Cancer
Last updated on July 2021Recruitment
- Recruitment Status
- Recruiting
- Estimated Enrollment
- Same as current
Summary
- Conditions
- Colorectal Cancer
- Type
- Interventional
- Phase
- Phase 2
- Design
- Allocation: Non-RandomizedIntervention Model: Single Group AssignmentMasking: None (Open Label)Primary Purpose: Treatment
Participation Requirements
- Age
- Between 21 years and 100 years
- Gender
- Both males and females
Description
Patients with radiologically-assessed locally advanced non-metastatic colorectal cancer will receive the following treatment before surgery: Colon cancers: One cycle of CAPEOX chemotherapy Two cycles of Pembrolizumab on Day 1 (concurrent with CAPEOX chemotherapy) and Day 22 Rectal cancers: Following...
Patients with radiologically-assessed locally advanced non-metastatic colorectal cancer will receive the following treatment before surgery: Colon cancers: One cycle of CAPEOX chemotherapy Two cycles of Pembrolizumab on Day 1 (concurrent with CAPEOX chemotherapy) and Day 22 Rectal cancers: Following completion of chemo-radiotherapy with 5-fluorouracil (5-FU)/ capecitabine, patients will receive 2 cycles of Pembrolizumab given 3 weeks apart Pre-operative biopsy and surgical samples as well as blood will be collected for translational studies.
Tracking Information
- NCT #
- NCT03984578
- Collaborators
- Merck Sharp & Dohme Corp.
- Investigators
- Principal Investigator: Iain Tan, MD National Cancer Centre, Singapore
Get Well Soon